智通财经APP讯，赛托生物(300583.SZ)公告，公司控股子公司山东斯瑞药业有限公司(简称“斯瑞药业”)近日收到欧洲药品质量管理局(简称“EDQM”)签发的原料药欧洲药典适用性证书(简称“CEP证书”)，化学原料药名称为：DEXAMETHASONE地塞米松。
地塞米松原料药可以用于生产地塞米松相关剂型药品，地塞米松是一种人工合成的长效肾上腺皮质激素类药物，具有强大的抗炎、抗过敏、抗休克及免疫抑制作用。临床常用于治疗类风湿性关节炎、系统性红斑狼疮等自身免疫性疾病，过敏性疾病(如严重的支气管哮喘、皮炎)，以及某些急性感染性疾病的辅助治疗(需与抗菌药物合用)，还可用于预防化疗药物引起的呕吐等。
更多港股重磅资讯，下载智通财经app
更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.